Related on Kindle
A practitioner read of HLF at $13.15 (7/10/26 close): a 40-year consumer franchise throwing off ~$668M of trailing adjusted EBITDA, an April 2026 senior-secured refinancing that locks in ~$45M of annual cash interest savings, and a deleveraging trajectory from 3.5x to 1.5x net — trading at multiples typically reserved for distressed businesses, not for a brand of this durability.
The Q2 print does not change the memo — it confirms the four pillars the case rests on. Fourth consecutive quarter of topline growth, Adj EBITDA at the upper end of guide, net leverage steady at 2.5x, H1 OCF up 52.5% Y/Y. FY 2026 reported EBITDA guidance was lowered to $670–690M (from $675–705M); constant-currency guidance was raised to $690–710M — the gap is FX. The one-time $94.6M debt-extinguishment loss is now booked and behind. Full anchor-table refresh in the Q2 2026 Print Addendum PDF below.
Net sales came in at $1.327B, up 5.4% year-over-year (5.8% constant currency) and at the top of the guidance range — Herbalife’s fourth straight quarter of reported and constant-currency net sales growth. Adjusted EBITDA of $166.6M landed at the upper end of the $150–170M guide, with constant-currency Adjusted EBITDA of $174.4M actually exceeding guidance. The reported net loss of $(26.3)M was driven by a $94.6M loss on extinguishment of debt tied to the April 29, 2026 senior-secured refinancing that the memo already contemplated. Per Note 8 of the 10-Q, that charge splits into approximately $49M of cash (the 6.125% call premium on the redeemed $800M 2029 Secured Notes) and approximately $46M of non-cash write-offs of unamortized debt discount and issuance costs on the retired 2024 Credit Facility and 2029 Secured Notes. It is one-time, is now behind the company, and pays back inside 13 months against the refi’s ~$45M annual cash-interest savings. Adjusted net income was $53.3M and adjusted diluted EPS was $0.51. Year-to-date operating cash flow reached $146.7M against $22.2M of capex. Management lowered the reported FY 2026 Adjusted EBITDA guidance to $670–690M (from $675–705M) — the ceiling came down $15M — while raising the constant-currency range to $690–710M (from $675–705M); the entire reported-vs-CC gap is FX. The reported cut is real and worth naming, even as the CC picture is favorable. Regional detail sharpens the read: Asia Pacific ex-China was up +23.1% constant currency, Latin America +8.2%, EMEA (5.6)%, China (29.0)%. The Asia-ex-China leg is doing the heavy lifting; China and EMEA remain the drags the memo has identified.
HLF closed at $12.60, down 1.56% on 2.15M shares (vs. 1.37M average daily volume — roughly 57% above normal). After-hours the stock moved to $12.25 (down another 2.78%). Market cap $1.31B; 52-week range $7.56 – $20.40. The valuation math updates cleanly: at $12.60, EV/TTM-Adjusted-EBITDA is ~4.2x (from 4.3x at $13.15 in the memo baseline). The market sold the print despite the top-of-guide beat on both net sales and constant-currency EBITDA and the guidance raise on constant currency — a discipline check on the memo’s core observation that HLF trades at a distress multiple against no distress fundamentals. If anything, today’s tape tightens the setup rather than loosening it.
John DeSimone (CFO) will retire December 31, 2026. Scott Schaefer succeeds him effective January 1, 2027. Announced in a separate press release August 5, 2026. A planned transition; the memo’s capital-structure and deleveraging architecture is not dependent on the individual seat.
Six-month comparison anchors on the Form 10-Q filed August 5, 2026 (SEC EDGAR accession 0001193125-26-335172) and the Q2 2026 earnings presentation. H1’25 Adjusted EBITDA implied from the presentation’s +1.1% Y/Y move on $342M current. All $ in millions.
| Metric | H1 2026 | H1 2025 | Y/Y $ | Y/Y % |
|---|---|---|---|---|
| Net sales | $2,644.0 | $2,480.8 | +$163.2 | +6.6% |
| Adjusted EBITDA | $342.3 | $338.6* | +$3.7 | +1.1% |
| Adj. EBITDA margin | 12.9% | 13.6%* | — | -70 bps |
| Operating cash flow | $146.7 | $96.2 | +$50.5 | +52.5% |
| Purchases of PP&E (capex) | ($22.2) | ($41.1) | +$18.9 | -46.0% |
| FCF proxy (OCF − capex) | $124.5 | $55.1 | +$69.4 | +126% |
| Total interest expense | ($89.5) | ($110.0) | +$20.5 | -18.6% |
* Adj. EBITDA H1’25 implied from Q2 2026 presentation disclosure that H1’26 Adj. EBITDA of $342M is +1.1% vs H1’25. Adj. EBITDA margin H1’25 computed as $338.6M / $2,480.8M.
Q2’26 quarterly cash flow and capex disclosed directly in the Q2 2026 press release; Q1’26 values derived by subtracting Q2 from the H1 total. Interest expense split from 10-Q disclosures ($40.0M in Q2 vs $89.5M H1 implies $49.5M in Q1). All $ in millions.
| Metric | Q1 2026 | Q2 2026 | H1 2026 |
|---|---|---|---|
| Net sales | $1,317.2 | $1,326.8 | $2,644.0 |
| Adjusted EBITDA | $175.7 | $166.6 | $342.3 |
| Adj. EBITDA margin | 13.3% | 12.6% | 12.9% |
| Operating cash flow | $113.8 | $32.9 | $146.7 |
| Purchases of PP&E (capex) | ($10.9) | ($11.3) | ($22.2) |
| FCF proxy (OCF − capex) | $102.9 | $21.6 | $124.5 |
| Total interest expense | ($49.5) | ($40.0) | ($89.5) |
Q2’26 interest expense of $40.0M vs Q2’25 of $55.4M is the refi’s ~$45M/year cash-interest savings already showing up in the reported quarter — a full-quarter beat of ~$15M vs prior-year comp, which annualizes to ~$62M against management’s $45M full-year guide. Q1 was the pre-refi quarter; Q2 is the first quarter reflecting the new capital structure. Q2’26 operating cash flow of $32.9M vs Q1’s $113.8M reflects normal working-capital seasonality (Q1 collects receivables from the Q4 selling season); the more relevant comparison is H1’26 OCF of $146.7M against H1’25’s $96.2M — up 52.5% Y/Y on 6.6% sales growth.
Read against the memo — the four-attribute case, updated: (1) Cheap valuation is intact. At $12.60 close, EV = market cap $1,321M + net debt $1,645M = $2,966M against TTM Adj EBITDA of ~$661M — ~4.5x EV/Adj EBITDA, at the trough end of the twelve-year range in the memo’s multiple-compression table. The market sold the top-of-guide print modestly (-1.56%) — a discipline check on the observation that HLF trades at a distress multiple against no distress fundamentals. (2) Low leverage is intact. Per HLF's Q2 2026 earnings presentation p25 (Credit Agreement EBITDA reconciliation schedule): Credit Agreement total debt (principal) $2,039.6M less cash $370.5M = net debt $1,669.1M, divided by TTM Credit Agreement EBITDA of $742.3M (which adds ~$81M of permitted items to reported Adj EBITDA — SBC, inventory write-downs, interest income, other) = net leverage 2.2x and total leverage 2.7x. One-tenth below year-end 2025 despite the refi noise, and well below the 3–4x historical band. Management’s <2.0x-by-end-of-2026 target remains in reach given the H1 FCF run. (3) Steady EBITDA is intact. Six consecutive quarters of Adjusted EBITDA in the $156–176M band. FY’26 reported Adj EBITDA guidance was lowered to $670–690M (from $675–705M); the constant-currency range was raised to $690–710M (from $675–705M). The entire reported-vs-CC gap is FX, not fundamentals. The reported cut is real, and worth naming. (4) Steady cash flow is intact. H1’26 OCF $146.7M against H1’25’s $96.2M is +52.5% Y/Y on 6.6% sales growth — the operating leverage the memo argued would emerge as refi savings started flowing. Q2’26 total interest expense of $40.0M vs Q2’25’s $55.4M is the $15M/quarter beat that annualizes to ~$62M against the $45M full-year guide. The Q2 print does not change the memo. It confirms it. Sources: HLF Q2 2026 earnings release (August 5, 2026); Q2 2026 earnings presentation; Form 10-Q for the quarter ended June 30, 2026 (SEC EDGAR, accession 0001193125-26-335172) — Note 4 (Long-Term Debt) and Note 8 (Loss on Extinguishment of Debt).
The full case study, valuation model, and library crosswalk — all free, all built from public filings.
HLF trades at $13.15 ($1.36B market cap; 7/10/26 close) — roughly 4.3x trailing EV/Adjusted EBITDA and 5.8x earnings — multiples typically reserved for distressed businesses, not for a brand throwing off ~$668M of trailing adjusted EBITDA. The April 29, 2026 senior-secured refinancing locks in ~$45M of annual cash interest savings, deleveraging from 2.1x net (2.7x total) at Q1 toward management's explicit <2.0x net target by end of 2026 and 1.5x by FY 2027. Cumulative debt repaid 2023–2028E projects at ~$1,315M — a 55% reduction from the 2022 peak.
Q1 2026 print reinforces the case. Herbalife raised FY 2026 Adjusted EBITDA guidance at the May 6, 2026 print to $675M–$705M (midpoint $690M, up from prior $670M–$710M), reflecting Q1 outperformance (Net Sales $1.317B, +7.8% YoY; Adjusted EBITDA $175.7M at 13.3% margin). Q2 2026 guidance sits at $150M–$170M Adjusted EBITDA. The balance sheet carries $451M cash and $400M undrawn revolver at Mar 31 — explicitly not distressed liquidity, even as the equity trades at a distress multiple. This is the gap the memo is walking.
Update · 12 July 2026: This memo has been refreshed with the 7/10/26 close ($13.15) and Wall Street's current one-year median target ($18.33). Fundamentals reconciled against the Q1 2026 10-Q (filed with the SEC) and the May 6, 2026 investor deck: 2.1x net / 2.7x total leverage, $175.7M Q1 Adjusted EBITDA, $668M TTM, $451M cash on hand, April 29 refi complete ($1.45B senior secured), management guiding to <2.0x net leverage by end of 2026 and $1.4B outstanding debt by end of 2028. Herbalife reports Q2 2026 results on August 5, 2026 — this memo publishes in the run-up to that print. Author position disclosed in footer.
Owner Earnings (Buffett method) at 8–10x post-refi run-rate: $26–$33. EV/Adjusted EBITDA at 5–7x consumer-staples-MLM-peer comp: $15–$25. DCF mid-case at 8.5% WACC: $28–$32. The lower-bound $14 reflects pure cycle-trough comp pricing; the upper-bound $28 reflects a partial re-rate toward consumer-staples norms. Vs. the $13.15 close (7/10/26), even the conservative lens implies meaningful upside. Wall Street's one-year median target ($18.33 per Yahoo Finance as of 7/10/26) sits mid-range in the $14–$28 band — external sanity check on the multiple lens. The LBO lens (5.1x EV/EBITDA at $17 entry, $250–350M annual FCF supporting rapid deleveraging) produces ~35% sponsor IRR over a 5-year hold — a sanity check that the underlying business supports the valuation case.
The multiple discount on HLF reads, in the author's view, as regulatory-tail-driven rather than fundamentals-driven. The market continues to price in the 2016 FTC consent-decree overhang and the MLM-business-model skepticism that intensified during the 2012–2019 Icahn-vs-Ackman battle — even as the business has continued to generate $617–668M of adjusted EBITDA every year for the last five. The April 2026 refinancing + the Bioniq personalization tuck-in ($55M base consideration over five years, up to $95M in contingent payments) + the Asia Pacific +20.8% constant-currency growth all suggest a business in transition that the market has not re-priced. The author's lens; not a price target, not a recommendation.
Independent editorial analysis · Not affiliated with or endorsed by Herbalife Ltd..
This case study is independent editorial and educational analysis of publicly available information about Herbalife Ltd.. The Baratelli Institute is not affiliated with, endorsed by, sponsored by, or otherwise connected to Herbalife Ltd.. Herbalife®, Herbalife Nutrition® and related marks are the property of their respective owners. No claim is made to any such marks by the Baratelli Institute. Analysis draws exclusively on publicly disclosed information (SEC filings, press releases, earnings call transcripts, investor materials, journalist reporting); no non-public information has been received from Herbalife Ltd.. Presented for educational and editorial purposes under principles of fair use and fair comment on a publicly traded company. Nothing in this analysis constitutes investment advice or a recommendation to buy, sell, or hold securities. Consult licensed advisors before investment decisions.
Ownership disclosure: The author, Phil Baratelli, currently owns HLF stock and has an economic interest in the security discussed in this case study. Readers should weigh the analysis with that bias in mind. This is an educational case study, not investment advice, not a research report, not a buy/sell rating, not a price target, not an allocation recommendation, not an opinion of fairness for any corporate transaction. Every number traces to a public SEC filing (10-K, 10-Q, 8-K, press releases). Readers considering an HLF position should consult their own qualified advisors and conduct their own diligence. The Institute is not a registered investment adviser; this is a Lowe v. SEC publisher-exception publication.
Every analytical move in this case study cross-references a Guide chapter. If you want to learn the methodology in full, the Guides are where it's taught.
“Practitioner case studies — written by an owner, the methodology of the Guides applied to a stock he owns, with the workpapers behind it.”
Financial Modeling & M&A · Pick the level that fits
Same practitioner voice at every tier — from the free acquisition records to the 800-page CFO reference.
Related free tools & libraries
Every one of these is a working calculator or reference — no signup, no gate.
Interactive weighted-average cost-of-capital calc with the Baratelli methodology.
73 company references plus the full methodology. Refreshed quarterly.
YTM, YTC, current yield — the fixed-income back-solve.
Macaulay, modified, and effective duration plus convexity adjustment.
Rolling maturity structure with cash-flow, yield, and duration outputs.
Tax-equivalent yield and after-tax comparison for muni holdings.
Sponsor-return math on a leverage-funded distribution.
Stock-based comp valuation via the closed-form Black-Scholes.
Discrete-time lattice for exotic vesting and early-exercise features.
Simulation-based value for TSR-linked performance awards.
Multi-period reinvestment and yield-on-cost across scenarios.
Full library — Apple to Nestle to Reliance. Snapshot inputs sourced to filings.
Berkshire, Danaher, Constellation, Blackstone, Apollo, LVMH, and 37 more.
Board-grade practitioner memos — LVMH, SpaceX, Dell, Disney, Belron.
One-page cheat sheet — formulas, conventions, sensitivity rules.
